Vincent Medical Holdings Limited (HK:1612)
:1612
Want to see HK:1612 full AI Analyst Report?
Top Page
Vincent Medical Holdings Limited
(1612)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$0.91
▲(9.64% Upside)
Action:Downgraded
Date:04/29/26
The score is driven primarily by improving financial performance but tempered by volatility and weak free-cash-flow conversion. Technicals are the main near-term drag (below key moving averages with negative MACD), while valuation is a clear positive (low P/E and solid dividend yield).
Positive Factors
Improving profitability
The company regained profitability after 2022, with materially wider gross and net margins in 2025. Sustained margin expansion and improved ROE indicate stronger pricing, product mix and cost control, supporting durable earnings power if trends continue.
Negative Factors
Weak free cash flow conversion
Free cash flow converts only about one‑third of accounting earnings, limiting internal funding for capex, R&D and working capital needs. The volatility of cash generation increases reliance on external financing and constrains predictable reinvestment and shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving profitability
The company regained profitability after 2022, with materially wider gross and net margins in 2025. Sustained margin expansion and improved ROE indicate stronger pricing, product mix and cost control, supporting durable earnings power if trends continue.
Read all positive factors
Vincent Medical Holdings Limited (1612) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$553.90M
Dividend Yield4.94%
Average Volume (3M)785.93K
Price to Earnings (P/E)5.1
Beta (1Y)0.65
Revenue Growth16.46%
EPS Growth50.51%
CountryHK
Employees1,328
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.16
Shares Outstanding659,399,840
10 Day Avg. Volume481,400
30 Day Avg. Volume785,933
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.81
Price to Sales (P/S)0.57
P/FCF Ratio9.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.12
Revenue Forecast (FY)HK$1.17B
Vincent Medical Holdings Limited Business Overview & Revenue Model
Company Description
Vincent Medical Holdings Limited, an investment holding company, researches, develops, manufactures, markets, and sells medical devices. It operates in two segments, Original Equipment Manufacturing (OEM) and Original Brand Manufacturing. The comp...
How the Company Makes Money
The company primarily makes money by selling medical consumables and devices used in respiratory care and hospital settings, generating revenue when products are delivered to customers (typically hospitals, healthcare institutions and medical dist...
Vincent Medical Holdings Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
71
Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 932.78M | 800.96M | 717.97M | 629.24M | 777.72M |
| Gross Profit | 327.44M | 259.99M | 240.39M | 147.83M | 243.83M |
| EBITDA | 155.33M | 100.00M | 104.43M | 29.95M | 114.55M |
| Net Income | 104.38M | 69.17M | 57.27M | -17.40M | 60.70M |
Balance Sheet | |||||
| Total Assets | 1.17B | 919.68M | 786.61M | 726.70M | 846.15M |
| Cash, Cash Equivalents and Short-Term Investments | 250.87M | 173.44M | 175.78M | 159.34M | 173.17M |
| Total Debt | 177.42M | 99.65M | 37.38M | 60.39M | 62.96M |
| Total Liabilities | 498.33M | 336.33M | 243.52M | 228.09M | 245.72M |
| Stockholders Equity | 664.65M | 578.55M | 541.84M | 498.01M | 598.36M |
Cash Flow | |||||
| Free Cash Flow | 54.64M | -26.52M | 61.28M | 57.67M | 94.48M |
| Operating Cash Flow | 168.42M | 73.48M | 124.97M | 76.27M | 119.43M |
| Investing Cash Flow | -119.77M | -98.81M | -62.37M | -18.61M | -20.69M |
| Financing Cash Flow | 27.34M | 26.39M | -45.37M | -67.84M | -101.16M |
Vincent Medical Holdings Limited Technical Analysis
Negative
0.83
Price Trends
0.91
Negative
0.92
Negative
0.92
Negative
Market Momentum
-0.02
Positive
38.06
Neutral
26.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1612, the sentiment is Negative. The current price of 0.83 is below the 20-day moving average (MA) of 0.86, below the 50-day MA of 0.91, and below the 200-day MA of 0.92, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.06 is Neutral, neither overbought nor oversold. The STOCH value of 26.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1612.
Vincent Medical Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$6.81B | 16.90 | 11.91% | 1.26% | 10.19% | 23.70% | |
67 Neutral | HK$6.54B | 18.02 | 9.25% | 1.88% | 29.19% | 121.25% | |
65 Neutral | HK$5.28B | 15.53 | 10.38% | 1.50% | 3.83% | -27.04% | |
64 Neutral | HK$553.90M | 5.13 | 16.21% | 4.94% | 16.46% | 50.51% | |
59 Neutral | HK$2.82B | 31.09 | 7.22% | ― | 20.65% | 127.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$3.49B | -6.72 | -11.27% | ― | 16.35% | 9.84% |
* Healthcare Sector Average
HK:1612
Vincent Medical Holdings Limited
0.84
0.44
110.00%
HK:9996
Peijia Medical Ltd.
5.24
-0.51
-8.87%
HK:6669
Acotec Scientific Holdings Limited
9.27
0.83
9.83%
HK:1789
AK Medical Holdings Ltd.
6.11
0.40
7.01%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
9.96
-0.13
-1.29%
HK:2172
MicroPort NeuroTech Limited
8.87
-1.09
-10.94%
Vincent Medical Holdings Limited Corporate Events
Vincent Medical Sets 2026 AGM to Approve Dividend, Board Mandates and Share Issue Authority
Apr 23, 2026
Vincent Medical Holdings has convened its annual general meeting for 20 May 2026 in Hong Kong, where shareholders will review the audited financial statements for the year ended 31 December 2025 and vote on a proposed final dividend of HK2.6 cents...
Vincent Medical Overhauls Constitution to Embrace HKEX Digital Regime
Apr 20, 2026
Vincent Medical Holdings Limited plans to overhaul its memorandum and articles of association to align with the latest Listing Rules of the Hong Kong Stock Exchange, including provisions for electronic and hybrid meetings, electronic voting, and t...
Vincent Medical Boosts Profit and Margins on Imaging Products Growth
Mar 25, 2026
Vincent Medical Holdings reported a strong set of annual results for the year ended 31 December 2025, with revenue rising 16.5% to HK$932.8 million and profit surging 52.8% to HK$108.4 million. Growth was driven primarily by its imaging disposable...
Vincent Medical Declares Final HK$0.026 Dividend for 2025
Mar 25, 2026
Vincent Medical Holdings Limited has declared a final ordinary cash dividend of HK$0.026 per share for the financial year ended 31 December 2025, subject to shareholder approval at a meeting scheduled for 20 May 2026. The dividend, payable in Hong...
Vincent Medical Sets March 25 Board Meeting on 2025 Results and Dividend
Mar 10, 2026
Vincent Medical Holdings has scheduled a board meeting for 25 March 2026 to review and approve its annual results for the year ended 31 December 2025, and to authorise the publication of those results. The board will also consider the payment of a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.